• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Research and Markets: Three of Boehringer Ingelheim's Current Major Products Are Forecast to Have Sales In Excess of EUR 1 Billion By 2010

Posted on: Tuesday, 5 September 2006, 12:01 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c41498) has announced the addition of Espicom Business Intelligence's Boehringer Ingelheim Prospects to 2010 to their offering.

Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

This company report provides Latest Results

A brief review of the latest report results

Executive Summary

At a glance understanding of the major trends and events affecting the company

Financial Analysis (current year)

Detailed P&L and investment review of the latest full year performance

Company Strategy

Where's the company going and how does it plan getting there?

Product/R&D Pipeline

Highly detailed monographs organised by therapeutic category. Also covers R&D strategy/pipeline and provides 5-year sales forecasts to 2010 for major launched products where available

Appendices

5-year financial assessment

Key agreements

Infrastructure

Key pharmaceutical subsidiaries/joint ventures

Product index

Boehringer Ingelheim is involved in the manufacturing and marketing of human pharmaceuticals (prescription medicines, consumer health care products), products for industrial customers (chemicals and biopharmaceuticals) and animal health. This report provides a full review of the company's activities together with sales forecasts for key products to 2010.

Boehringer Ingelheim GmbH is the world's largest private pharmaceutical enterprise, encompasses more than 152 affiliates in 45 countries, and employing over 34,000 people. The company's activities are concentrated on two businesses: Human Pharmaceuticals and Animal Health.

Within the Prescription Medicines division, BI markets products in the following therapeutic areas: Respiratory, Cardiovascular, Immunology and Inflammation, Urology, Central Nervous System and Virology. Research and development is focused on developing treatments in the following fields: Respiratory, Cardiovascular, Immunology and Inflammation, Central Nervous System, Virology, Metabolic and Oncology.

Current Growth Drivers

Three of BI's current major products are forecast to have sales in excess of EUR 1 billion by 2010, forming the foundations of short to medium growth in the prescription pharmaceutical sector.

Spiriva (tiotropium bromide) is a novel, once-daily, inhaled treatment for chronic obstructive pulmonary disease.

Micardis (telmisartan) is an angiotensin-II receptor blocker for the once-daily treatment of hypertension.

Mobic (meloxicam) is a non-steroidal anti-inflammatory drug for the treatment of rheumatoid arthritis and osteoarthritis.

For more information visit http://www.researchandmarkets.com/reports/c41498

Source: Business Wire

More News in this Category